Is there a benefit on survival of tyrosine-kinase inhibitors versus chemotherapy in first line in mutated EGFR patients with advanced non-small cell cancer (NSCLC)? A meta-analysis. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback